Overview

Detailed Summary

Auro Laboratories Ltd specializes in the manufacturing of generic Active Pharmaceutical Ingredients (APIs), with a primary focus on anti-diabetic medications like Metformin HCL.
The company is serving international markets, exporting a significant portion of its production to regions such as South East Asia, the Middle East, and Europe.
With a current capacity of 1800 MTPA for Metformin HCL, Auro Laboratories plans to double this capacity, signaling a strong growth trajectory.
The company's manufacturing facilities are ISO 9001:2000 and WHO-cGMP certified, which reinforces their commitment to high-quality production standards.

Sector: Pharmaceuticals
Industry: Pharmaceuticals - Indian - Bulk Drugs
Market Cap: 182 Cr
Volatility: Moderate Risk
P/E Ratio: 62.0
Industry P/E: 56.7
PEG Ratio: —
P/B Ratio: 4.2
52W High: 317.00
52W Low: 159.00

Sales CAGR

1Y: -63.83%
3Y: -27.48%
5Y: -15.03%
10Y: -4.53%

Profit CAGR

1Y: -76.38%
3Y: -13.54%
5Y: -14.63%
10Y: 8.51%

ROE

TTM: 4.47%
3Y: 10.13%
5Y: 12.33%
10Y: 14.36%

ROCE

TTM: 7.31%
3Y: 10.33%
5Y: 13.89%
10Y: 16.54%

Technicals

‌

Forecasts

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
AAREYDRUGS	70.19	200 Cr	66.22	1.38	0.00	2.41	5.22	1.17
OXYGENTAPH	50.60	187 Cr	-10.33	0.00	0.00	46.67	-53.26	-15.44
AUROLAB	294.00	182 Cr	62.03	4.23	0.00	4.47	7.31	1.55
ASTONEALAB	159.00	167 Cr	22.91	2.98	0.00	8.67	10.26	3.81
KIMIABL	30.26	143 Cr	15.84	12.36	0.00	70.62	33.57	8.92
SMRUTHIORG	123.00	140 Cr	30.67	1.98	1.22	6.60	10.56	4.61
PANCHSHEEL	104.70	138 Cr	11.21	1.00	0.76	8.89	11.28	7.21

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2024	Jun 2025	Sep 2025
Sales	3.10	2.77	8.84
Expenses	2.38	2.75	6.48
Operating Profit	0.72	0.02	2.36
OPM %	23.23	0.72	26.70
Other Income	0.31	0.42	0.98
Interest	0.28	0.28	0.96
Depreciation	0.27	0.27	0.65
Profit Before Tax	0.48	-0.11	1.72
Tax %	25.00	0.00	58.14
Net Profit	0.36	-0.11	0.72
EPS in Rs	0.57	-0.17	1.15

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	37	41	47	44	54	51	53	54	19	16
Expenses	31	35	40	38	43	46	49	43	16	14
Operating Profit	5.85	6.23	6.84	6.27	11	4.63	4.39	11	3.40	2.00
OPM %	15.82	15.28	14.61	14.32	20.72	9.09	8.30	19.89	17.54	12.25
Other Income	0.53	0.51	0.96	0.97	0.76	1.09	0.94	1.50	0.66	1.00
Interest	1.07	1.09	0.72	0.58	0.46	0.83	0.81	0.74	1.08	1.11
Depreciation	0.86	0.93	1.01	1.02	1.04	1.02	1.07	1.09	1.10	1.10
Profit Before Tax	2.92	4.73	6.07	5.64	11	3.87	3.45	10	1.88	0.79
Tax %	72.11	25.34	27.51	28.13	31.66	26.57	29.13	24.68	2.24	12.66
Net Profit	0.82	3.53	4.40	4.05	7.18	2.84	2.44	7.79	1.84	0.69
EPS in Rs	4.70	7.59	7.06	6.50	11.54	4.56	3.92	12.41	2.49	4.74
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23	6.23
Reserves	2.35	3.18	6.75	11	15	22	25	28	36	37
Borrowings	13	4.95	9.20	8.09	3.16	3.05	14	6.41	26	43
Other Liabilities	4.48	12	8.23	7.96	7.69	10	9.66	15	18	13
Total Liabilities	26	27	30	33	32	42	55	56	86	99
Fixed Assets	9.13	13	13	15	14	14	14	13	22	21
CWIP	3.33	0.23	1.07	0.12	0.12	0.13	3.68	7.67	33	56
Investments	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05
Other Assets	13	14	16	19	18	28	38	36	31	22
Total Assets	26	27	30	33	32	42	55	56	86	99

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	7.88	6.49	6.05	6.87	9.30	13	-6.59	3.28	19	5.75
Cash from Investing Activity	-2.44	-2.20	-3.04	-3.19	-2.21	-3.51	-5.34	-5.08	-39	-24
Cash from Financing Activity	-5.34	-3.81	-1.77	-1.83	-5.52	-0.46	9.79	-8.18	19	18
Net Cash Flow	0.09	0.47	1.24	1.86	1.58	8.85	-2.14	-9.98	-0.77	-1.02

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Promoters	52.09%	52.09%	52.09%	52.09%	52.15%	52.15%	52.15%	52.15%	52.18%	52.18%	52.18%	52.18%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
DIIs	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Public	47.90%	47.90%	47.90%	47.90%	47.84%	47.84%	47.84%	47.84%	47.82%	47.82%	47.82%	47.82%
Total Shareholders	10,906	10,501	10,272	9,905	9,441	9,335	9,266	9,265	9,102	8,916	8,860	8,640

Market Transactions

Unlock Premium Features

Analyst Target, Price, EPS and Revenue Projections

Upgrade

Projection

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.